Frieling JS - Search Results

1

Targeted Deletion of Cxcl1 in MSCs Promotes Osteogenesis and Suppresses Bone Metastatic Prostate Cancer.

Johnson CS, Costanzo-Garvey D, Valencia JC, Rajgopal S, Reed T, Brannon ER, Frieling JS, Mosley DD, Wyatt TA, Edmondson EF, Mohan K, Mathew G, Cook LM. Johnson CS, et al. Among authors: frieling js. Mol Cancer Res. 2025 Apr 29. doi: 10.1158/1541-7786.MCR-24-0672. Online ahead of print. Mol Cancer Res. 2025. PMID: 40298918

2

Neutrophils are mediators of metastatic prostate cancer progression in bone.

Costanzo-Garvey DL, Keeley T, Case AJ, Watson GF, Alsamraae M, Yu Y, Su K, Heim CE, Kielian T, Morrissey C, Frieling JS, Cook LM. Costanzo-Garvey DL, et al. Among authors: frieling js. Cancer Immunol Immunother. 2020 Jun;69(6):1113-1130. doi: 10.1007/s00262-020-02527-6. Epub 2020 Feb 29. Cancer Immunol Immunother. 2020. PMID: 32114681 Free PMC article.

3

Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis.

Cook LM, Frieling JS, Nerlakanti N, McGuire JJ, Stewart PA, Burger KL, Cleveland JL, Lynch CC. Cook LM, et al. Among authors: frieling js. Oncogene. 2019 Oct;38(44):6959-6969. doi: 10.1038/s41388-019-0913-4. Epub 2019 Aug 13. Oncogene. 2019. PMID: 31409900 Free PMC article.

4

Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer.

McGuire JJ, Frieling JS, Lo CH, Li T, Muhammad A, Lawrence HR, Lawrence NJ, Cook LM, Lynch CC. McGuire JJ, et al. Among authors: frieling js. Nat Commun. 2021 Feb 1;12(1):723. doi: 10.1038/s41467-021-20962-6. Nat Commun. 2021. PMID: 33526787 Free PMC article.

5

Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer.

Araujo A, Cook LM, Frieling JS, Tan W, Copland JA 2nd, Kohli M, Gupta S, Dhillon J, Pow-Sang J, Lynch CC, Basanta D. Araujo A, et al. Among authors: frieling js. Cancers (Basel). 2021 Feb 8;13(4):677. doi: 10.3390/cancers13040677. Cancers (Basel). 2021. PMID: 33567529 Free PMC article.

6

Tales of Cancer-Induced Bone Disease from the Senescent Osteocyte Crypt.

Frieling JS, Lynch CC. Frieling JS, et al. Cancer Res. 2024 Dec 2;84(23):3917-3918. doi: 10.1158/0008-5472.CAN-24-3611. Cancer Res. 2024. PMID: 39618247

7

γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer.

Frieling JS, Tordesillas L, Bustos XE, Ramello MC, Bishop RT, Cianne JE, Snedal SA, Li T, Lo CH, de la Iglesia J, Roselli E, Benzaïd I, Wang X, Kim Y, Lynch CC, Abate-Daga D. Frieling JS, et al. Sci Adv. 2023 May 3;9(18):eadf0108. doi: 10.1126/sciadv.adf0108. Epub 2023 May 3. Sci Adv. 2023. PMID: 37134157 Free PMC article.

8

Current and emerging therapies for bone metastatic castration-resistant prostate cancer.

Frieling JS, Basanta D, Lynch CC. Frieling JS, et al. Cancer Control. 2015 Jan;22(1):109-20. doi: 10.1177/107327481502200114. Cancer Control. 2015. PMID: 25504285 Free PMC article. Review.

9

Emerging roles for stromal cells in bone metastasis.

Nyman KJ, Frieling JS, Lynch CC. Nyman KJ, et al. Among authors: frieling js. J Bone Oncol. 2024 May 17;47:100610. doi: 10.1016/j.jbo.2024.100610. eCollection 2024 Aug. J Bone Oncol. 2024. PMID: 38984147 Free PMC article.

10

Prostate cancer-derived MMP-3 controls intrinsic cell growth and extrinsic angiogenesis.

Frieling JS, Li T, Tauro M, Lynch CC. Frieling JS, et al. Neoplasia. 2020 Oct;22(10):511-521. doi: 10.1016/j.neo.2020.08.004. Epub 2020 Sep 5. Neoplasia. 2020. PMID: 32896761 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters